International Medical Case Reports Journal (Aug 2023)
Sacubitril/Valsartan Shows Improvement of the Cardio-Ankle Vascular Index in a Hypertensive Patient
Abstract
Kazuhiro Shimizu,1 Tsuyoshi Tabata,2 Masahiro Iwakawa,1 Shuji Sato,1 Toshio Kinoshita1,2 1Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan; 2Department of Clinical Functional Physiology (Sakura), Toho University Sakura Medical Center, Chiba, JapanCorrespondence: Kazuhiro Shimizu, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba, 285-8741, Japan, Tel +81-43-462-8811, Fax +81-43-462-8820, Email [email protected]: A 72-year-old man presented to our clinic with hypertension. Arterial stiffness evaluated by cardio ankle vascular index (CAVI) was markedly increased at 13.5. We treated him using 80 mg/day of valsartan for three months. CAVI was decreased from 13.5 to 13.0. However, his BP fluctuations were still high. We changed the treatment to angiotensin receptor-neprilysin inhibitor (ARNI) with increasing doses up to 400 mg. Independent of the change in blood pressure at the time of measurement, CAVI improved with ARNI dose. Hypertension treatment with an awareness of the cardio-vascular interaction might be a possibility prevents future heart failure development effectively.Keywords: hypertension, angiotensin receptor-neprilysin inhibitor, arterial stiffness, cardio ankle vascular index
